Loading news...
Royalty Pharma plc (RPRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty business in Asia. Ken joins Royalty Pharma from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.
NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zymeworks Inc. (Nasdaq: ZYME) today announced an agreement for $250 million in funding from Royalty Pharma in the form of a non-recourse royalty-backed note with repayments due from 30% of worldwide tiered royalties on Ziihera® (zanidatamab-hrii) owed to Zymeworks from Jazz Pharmaceuticals (Jazz) and BeOne Medicines (BeOne).
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) was the target of a significant drop in short interest in the month of February. As of February 13th, there was short interest totaling 13,443,797 shares, a drop of 49.2% from the January 29th total of 26,462,455 shares. Based on an average trading volume of 4,434,841 shares,
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m. ET.
Heartland Advisors Inc. acquired a new position in shares of Royalty Pharma PLC (NASDAQ: RPRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 96,553 shares of the biopharmaceutical company's stock, valued at approximately $3,406,000. Several other institutional investors and hedge funds also
Royalty Pharma delivered robust FY25 results, with double-digit growth in Royalty Receipts and Portfolio Receipts, and disciplined capital deployment. RPRX expanded its portfolio through $2.6B in new royalty transactions, $1.2B in share repurchases, and a 7% dividend increase entering 2026. Synthetic royalties emerged as a major growth engine, surpassing traditional royalties in announced transaction value and offering structural advantages for biopharma funding.
Royalty Pharma (NASDAQ: RPRX) executives highlighted what they described as a "landmark year" in 2025, pointing to double-digit top-line growth, continued capital deployment into new royalty deals, and a significant strategic change with the internalization of the company's external manager. Management also laid out 2026 guidance that calls for mid-single-digit growth in recurring royalty receipts while
Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns.
Royalty Pharma plc (RPRX) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Portfolio Rece ipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025 Net cas h provided by operating activities of $827 million in Q4 2025 and $2,490 million for FY 2025 Full year 2026 guidance: Portfolio Receipts expected to be $3,275 million to $3,425 million NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts. “We had one of the most remarkable years in Royalty Pharma's history in 2025,” said Pablo Legorreta, Royalty Pharma's Chief Executive Officer and Chairman of the Board.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 114,954 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total value of $4,924,629.36. Following the sale, the chief financial officer owned 23,972 shares in the company,
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 108,424 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $42.08, for a total transaction of $4,562,481.92. Following the sale, the chief financial officer owned 30,167 shares of the company's stock, valued
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cullen Frost Bankers Inc. boosted its holdings in Royalty Pharma PLC (NASDAQ: RPRX) by 44.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 457,097 shares of the biopharmaceutical company's stock after acquiring an additional 140,542 shares during the quarter. Cullen
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 69,582 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $39.35, for a total transaction of $2,738,051.70. Following the transaction, the chief financial officer directly owned 36,010 shares in the company,
Allstate Corp bought a new position in Royalty Pharma PLC (NASDAQ: RPRX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,894 shares of the biopharmaceutical company's stock, valued at approximately $455,000. A number of other institutional investors have also recently
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.